The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase III study (APROMISS) of AL3818 (Catequentinib, Anlotinib) hydrochloride monotherapy in subjects with metastatic or advanced synovial sarcoma.
 
Brian Andrew Van Tine
Leadership - Polaris
Consulting or Advisory Role - Adaptimmune; ADRx; Apexigen; Bayer; Cytokinetics; Daiihi Sankyo; Deciphera; EMD Serono; Epizyme; GlaxoSmithKline; Immune Design; Lilly; Novartis; Pfizer
Speakers' Bureau - Adaptimmune; GlaxoSmithKline; Lilly; Novartis
Research Funding - GlaxoSmithKline; Merck; Pfizer; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Accuronix Therapeutics- Licensing agreement. Sigma-2 Receptor Ligands and Therapeutic uses therefor (006766), • Modular Platform for Targeted Therapeutic Delivery (006755), • Sigma-2 Receptor Ligand Drug Conjugates as Antitumor Compounds, Methods of synth; Patent on ALEXT3102; Patent on the use of ME1 as a biomarker
Expert Testimony - Health Advances
Travel, Accommodations, Expenses - Adaptimmune; Advenchen Laboratories; GlaxoSmithKline; Lilly
 
Sant P. Chawla
Stock and Other Ownership Interests - AADi; Cellestia Biotech; Immix BioPharma
Honoraria - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma; Tyme
Consulting or Advisory Role - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Speakers' Bureau - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Research Funding - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Janssen; Karyopharm Therapeutics; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
 
Jonathan C. Trent
Consulting or Advisory Role - Agios; Bayer; Blueprint Medicines; C4 Therapeutics; Daiichi Sankyo; Deciphera; Epizyme; Janssen; Lilly; Novartis
 
Breelyn A. Wilky
Honoraria - GlaxoSmithKline
Consulting or Advisory Role - Adaptimmune; Daiichi Sankyo; Deciphera; SpringWorks Therapeutics
Research Funding - Agenus
Travel, Accommodations, Expenses - Adaptimmune; Daiichi Sankyo; Deciphera
 
Rashmi Chugh
Consulting or Advisory Role - Deciphera; Deciphera; Ipsen
Research Funding - AADi (Inst); Advenchen Laboratories (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MabVax (Inst); Medivation (Inst); Morphotek (Inst); Mundipharma (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst); Qilu Puget Sound Biotherapeutics (Inst); Qilu Puget Sound Biotherapeutics (Inst); SpringWorks Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Wolters Kluwer
Travel, Accommodations, Expenses - SpringWorks Therapeutics
 
Bartosz Chmielowski
Consulting or Advisory Role - Deciphera; Epizyme; Genentech; IDEAYA Biosciences; Iovance Biotherapeutics; Nektar; OncoSec; Sanofi
Speakers' Bureau - Sanofi/Regeneron
Research Funding - Advenchen Laboratories (Inst); Aeglea Biotherapeutics (Inst); Array BioPharma (Inst); Ascentage Pharma (Inst); Atreca (Inst); Biothera (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); IDEAYA Biosciences (Inst); Idera (Inst); Immunocore (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Iovance Biotherapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Neon Therapeutics (Inst); Novartis (Inst); PACT Pharma (Inst); RAPT Therapeutics (Inst); Replimune (Inst); Rgenix (Inst); Tolero Pharmaceuticals (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Deciphera; Epizyme; Regeneron
 
Shivaani Kummar
Stock and Other Ownership Interests - Arxeon Therapeutics (I); PathomIQ
Honoraria - Bayer
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Cadila Pharmaceuticals (I); Gilead Sciences; Harbour BioMed; MedTree (I); Mundipharma; Seagen; ShangPharma Innovation; SpringWorks Therapeutics
Research Funding - ADC Therapeutics (Inst); Advenchen Laboratories (Inst); Amgen (Inst); Astex Pharmaceuticals (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Dynavax Technologies (Inst); Genome & Company (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Loxo (Inst); Moderna Therapeutics (Inst); Pfizer (Inst); Plexxikon (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Bayer
 
Atrayee Basu Mallick
Stock and Other Ownership Interests - Alexion Pharmaceuticals (I); BMS (I); Pfizer (I)
Consulting or Advisory Role - Daichi Sanyo
Research Funding - Advenchen Laboratories (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); The Academic GI Cancer Consortium (Inst); TRACON Pharma (Inst)
 
Neeta Somaiah
Stock and Other Ownership Interests - JNJ (I); Pfizer (I)
Consulting or Advisory Role - Bayer; Bayer; Blueprint Medicines; Deciphera; Immune Design
Research Funding - Ascentage Pharma; Ascentage Pharma; Ascentage Pharma; Daiichi Sankyo/Lilly; Deciphera; GlaxoSmithKline; Karyopharm Therapeutics; MedImmune
 
Lee D. Cranmer
No Relationships to Disclose
 
Mark Agulnik
Consulting or Advisory Role - Adaptimmune; AstraZeneca; Lilly; Regeneron
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Deciphera
Research Funding - Exelixis (Inst)
 
Vicki Leigh Keedy
Consulting or Advisory Role - Daiichi Sankyo/Lilly; Karyopharm Therapeutics
Research Funding - Adaptimmune (Inst); Advenchen Laboratories (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Lilly (Inst); medpacto (Inst); Plexxikon (Inst); SpringWorks Therapeutics (Inst); TRACON Pharma (Inst)
 
Silvia Stacchiotti
Honoraria - GlaxoSmithKline; Lilly; Novartis; PharmaMar
Consulting or Advisory Role - Bavarian Nordic; Bayer; Daiichi Sankyo; Deciphera; Epizyme; GlaxoSmithKline; Lilly; MaxiVax; Novartis; PharmaMar
Research Funding - Advenchen Laboratories (Inst); Amgen (Inst); Bayer (Inst); Blueprint Medicines; Daiichi Sankyo (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); SpringWorks Therapeutics (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Bruno Vincenzi
No Relationships to Disclose
 
Giuseppe Badalamenti
No Relationships to Disclose
 
Brittany L Siontis
Consulting or Advisory Role - Deciphera (Inst)
Research Funding - Deciphera (Inst)
 
Steven Attia
Research Funding - AB Science (Inst); Adaptimmune (Inst); Advenchen Laboratories (Inst); Bavarian Nordic (Inst); Bayer (Inst); Blueprint Medicines (Inst); BTG (Inst); CBA Pharma (Inst); Deciphera (Inst); Desmoid Tumor Research Foundation; Epizyme (Inst); FORMA Therapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Gradalis (Inst); Immune Design (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Philogen (Inst); PTC Therapeutics (Inst); SpringWorks Therapeutics (Inst); Takeda (Inst); TRACON Pharma (Inst)